Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma

Table 3 Baseline demographic and clinical characteristics of the patients, mean ± SE/n (%)

Characteristics	Total (n = 50)	GemCis group (n = 31)	GemCis + IDA-TACE group (n = 19)	P value
Age, years, median (IQR)	56.5 (48.0-63.0)	57.0 (48.0-63.0)	56.0 (48.0-63.0)	0.976
Gender
Male	30 (60.0)	18 (58.1)	12 (63.2)	0.721
Female	20 (40.0)	13 (41.9)	7 (36.8)
ECOG performance status
0	16 (32.0)	9 (29.0)	7 (36.8)	0.566
1	34 (68.0)	22 (71.0)	12 (63.2)
Nodules
Single	23 (46.0)	15 (48.4)	8 (42.1)	0.665
Multiple	27 (54.0)	16 (51.6)	11 (57.9)
AJCC stage
I	6 (12.0)	4 (12.9)	2 (10.5)	0.951
II	11 (22.0)	7 (22.6)	4 (21.1)
III	17 (34.0)	11 (35.5)	6 (31.6)
IV	16 (32.0)	9 (29.0)	7 (36.8)
Largest nodule
≤ 5	28 (56.0)	19 (61.3)	9 (47.4)	0.336
> 5	22 (44.0)	12 (38.7)	10 (52.6)
Child-Pugh class
A	43 (86.0)	25 (80.6)	18 (94.7)	0.229
B	7 (14.0)	6 (19.4)	1 (5.3)
Extrahepatic spread
Absent	17 (34.0)	11 (35.5)	6 (31.6)	0.900
Present
Single metastasis	24 (48.0)	15 (48.4)	9 (47.4)
Multiple metastases	9 (18.0)	5 (16.1)	4 (21.1)
CA199, U/mL
≤ 37	12 (24.0)	6 (19.4)	6 (31.6)	0.496
> 37	38 (76.0)	25 (80.6)	13 (68.4)
CA125, U/mL
≤ 35	27 (54.0)	15 (48.4)	12 (63.2)	0.309
> 35	23 (46.0)	16 (51.6)	7 (36.8)
TBIL, μmol/mL, median (IQR)	11.2 (7.5-21.6)	11.2 (7.6-48.5)	10.3 (7.2-19.6)	0.556
Albumin, g/L	41.3 ± 6.4	42.0 ± 7.5	40.1 ± 4.1	0.302
RBC, × 109/L	4.4 ± 0.8	4.4 ± 0.9	4.3 ± 0.8	0.770
WBC, × 109/L	7.45 ± 3.1	7.7 ± 2.9	7.0 ± 3.4	0.454
Platelet, × 109/L	216.8 ± 82.1	229.8 ± 89.5	195.6 ± 66.2	0.156
PT, seconds	13.3 ± 1.2	13.4 ± 1.2	13.1 ± 1.2	0.537

IDA: Idarubicin; GemCis: Gemcitabine and cisplatin; TACE: Transarterial chemoembolization; ECOG: Eastern cooperative oncology group; AJCC: American Joint Committee on Cancer; RBC: Red blood cells; WBC: White blood cells; IQR: Interquartile range; CA: Carbohydrate antigen; TBIL: Total bilirubin; PT: Prothrombin Time.